Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
$49.95
-$0.23(-1.55%)
At close: 4:00 PM EST
$49.95
-$0.23(-1.55%)
Day’s Range― - ―
52-Week Range$12.21 - $52.47
Previous CloseN/A
Volume154.73K
Average Volume (3M)451.11K
Market Cap
$1.38B
Enterprise Value$1.62B
Total Cash (Recent Filing)$248.96M
Total Debt (Recent Filing)$346.45M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 09, 2026EPS Estimate
0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.52
Shares Outstanding27,688,470
10 Day Avg. Volume422,424
30 Day Avg. Volume451,113
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)5.30
Price to Sales (P/S)4.12
P/FCF Ratio-2.77
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue9.56
Enterprise Value/Gross Profit98.36
Enterprise Value/Ebitda-354.41
Forecast
1Y Price Target
$74.13Price Target Upside48.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.1
Revenue Forecast (FY)$120.73M
Bulls Say, Bears Say
Bulls Say
Clinical Safety ProfileTolerable safety findings for rosnilimab in the ulcerative colitis study reduce safety concerns for higher dosing and support continued development in immune-mediated diseases.
Mechanism Of Action And RA EfficacySustained PD-1 activity coupled with T cell depletion and encouraging rheumatoid arthritis data focus the program on RA and increase the probability of a successful targeted development path.
Partnering Interest For PD-1 AgonistDe-risked clinical results position the PD-1 agonist as an attractive asset for large pharmaceutical companies, creating potential for strategic partnerships or non-dilutive deals.
Bears Say
Clinical Efficacy Setback In Ulcerative ColitisFailure to meet the primary endpoint in the ulcerative colitis trial would suggest T cell targeting may not drive that disease and could undermine confidence in that development route.
Legal Risk And Revenue ImpactAn unfavorable litigation outcome could reduce revenue from Jemperli and increase legal expenses, weighing on cash flow and investor sentiment.
License And Royalty Dilution RiskA court decision granting an irrevocable license could allow a partner to negotiate lower royalties and milestone payments, materially cutting future income from the asset.
AnaptysBio News
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.21 and its highest was $52.47 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $1.38B.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Mar 09, 2026 which is in 26 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Nov 04, 2025. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of -$1.214 by $1.734.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is 0.86.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 27,688,470 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of $0.52 in its last earnings report, beating expectations of -$1.214. Following the earnings report the stock price went up 3.627%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnaptysBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.13 (48.41% Upside)
$74.13 (48.41% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 15.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $723.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
242.59%
12-Months-Change
Fundamentals
Return on Equity
-308.02%
Trailing 12-Months
Asset Growth
-28.44%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$74.13
▲(48.41% Upside)
Technical Analysis
Meiragtx Holdings
―
Keros Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Terns Pharmaceuticals
―
Ownership Overview
Currently, No data available
---